Overall, in ER+ breast cancer cells expressing functional Rb, standard-of-care treatment for breast cancer (fulvestrant + palbociclib) induced senescence that was reversible and, therefore, could mediate tumor relapse. Here, ESR1 is linked to breast cancer.